Compare Sanofi SA (SNY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard S&P 500 ETF — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Vanguard S&P 500 ETF trades at $701.71. The key difference: Sanofi SA pays a 5.65% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VOO | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $714.90 |
52-Week Low | $41.33 | $580.93 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
VOO trades at $704.09, down 0.56% on the day, with a neutral technical signal and bullish moving averages. Support is firm near $701, while resistance sits at $707. The ETF remains a core S&P 500 holding, with recent news highlighting its tax efficiency versus gold ETFs and strong inflows amid record ETF launches in 2026.
Long-term outlook remains positive given historical S&P 500 performance, though risks include elevated market valuations and Fed policy uncertainty. The ETF offers broad market exposure, but investors face potential volatility from macroeconomic factors and high concentration in top AI-driven companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
